Bioptigen Introduces Dynamic 3D Tissue Flattening Software for Envisu SD-OCT Systems (See Video)
Software is first to enable continuous optical sectioning along true anatomical contours
Bioptigen Inc. announced today the introduction of Envisu Apps, modular image processing software for improved analysis and visualization of high resolution volumetric OCT images. The first app, named Dynamic 3D Tissue Flattening uses fully automated retinal layer segmentations for enhanced en face views. These retinal layer segmentations allow users to eliminate motion artifacts (such as respiration, cardiac, etc.) which often occur during in vivo image acquisition, thus en face views appear perfectly flat across the entire image.
“Single pixel slices are possible across the whole 3D image, allowing uniform sampling of data along a warped contour that ‘cuts’ through the center of features as small as a single capillary bed”, said Eric Buckland, President and CEO of Bioptigen. “This is a game‐changer as it allows dynamic exploration of flattened data, another important step towards true optical histology via SD‐OCT”.
The software enables users to more easily discover pathologies, and features of interest, and makes possible the export of pure, flattened single image frames via snapshots for written publications, or video montages of tissue fly‐throughs for conference presentations. The Dynamic Flattening software enables users to display tissue‐specific data across the whole field of view. Instead of slicing along the X‐Y‐Z voxel grid, this tool allows users to explore their data along anatomically relevant planes, enabling for the first time full depth tissue fly‐throughs.
The Dynamic 3D Tissue Flattening software module, which works in concert with Bioptigen’s Diver 2.0 Auto‐segmentation software includes an intuitive graphical user interface, and comes with easy setup, installation, and use protocols. The software is available free to Bioptigen Envisu Research systems customers, by writing to email@example.com.
Below are videos illustrating examples of this application used for data visualization.
Bioptigen R-class products are contraindicated for use with humans.
Deployed in top ophthalmic research and clinical institutions worldwide, Bioptigen devices are covered by 60‐plus patent applications, including 40 awarded patents. More than 300 scientific articles have been published citing data acquired with Bioptigen technologies. Learn more about Bioptigen and its technologies at www.bioptigen.com.